相关实验视频
Updated: May 8, 2026

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.0K
从虚拟患者到免疫瘤学中的数字双胞胎:从机械定量系统药理学建模中吸取的经验教训
ArXiv
|March 18, 2024
概括
虚拟患者和数字双胞胎显示出加速免疫瘤学药物开发的前景. 它们的生成和应用存在挑战,特别是数字双胞胎需要研究特定的模型.
科学领域:
- 计算生物学是一种计算生物学.
- 翻译医学是一种翻译医学.
- 免疫瘤学 免疫瘤学
背景情况:
- 虚拟患者和数字双胞胎是新兴的医疗保健概念.
- 这些技术旨在加快药物开发并提高患者的生存率.
- 目前的应用,特别是免疫瘤学,面临着局限性.
研究的目的:
- 讨论创建免疫瘤学虚拟患者群体的挑战.
- 审查在医疗保健中开发数字双胞胎的举措.
- 探索虚拟患者和数字双胞胎研究如何相互信息化.
主要方法:
- 对虚拟患者生成现有方法的审查.
- 分析免疫瘤学应用所面临的挑战.
- 讨论数字双胞胎发展的要求和方法.
主要成果:
- 虚拟患者在当前免疫瘤学研究中的应用有限.
- 数字双胞胎通常需要针对临床环境量身定制的特定研究模型.
- 经验凸显了对强大的生成方法和数据集成的需求.
结论:
- 解决虚拟患者和数字双胞胎世代面临的挑战对于推动免疫瘤学的发展至关重要.
- 需要进一步的研究来完善模型和数据要求.
- 这两种概念的协同发展可以加速治疗的突破.
更多相关视频
相关概念视频
Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

